Literature DB >> 12676780

Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features.

Anna Guarini1, Gianluca Gaidano, Francesca Romana Mauro, Daniela Capello, Francesca Mancini, Maria Stefania De Propris, Marco Mancini, Enrica Orsini, Massimo Gentile, Massimo Breccia, Antonio Cuneo, Gianluigi Castoldi, Robert Foa.   

Abstract

Different biologic features have been associated with a more or less aggressive clinical course in chronic lymphocytic leukemia (CLL). In the present study, 20 patients with highly stable CLL observed at a single institution over a period of 10 to 23 years and who never required treatment were extensively characterized. The aim was to identify a distinct and reproducible biologic profile associated with disease stability that may be used to recognize at presentation CLL patients who are likely to have a very benign clinical course and for whom treatment is not indicated. The results obtained indicate that numerous parameters are closely associated with disease stability: a typical CLL morphology and immunophenotype, the lack of expression of the CD38 antigen, the mutated immunoglobulin (Ig) heavy (H) chain variable (V) pattern, the absence of p53 mutations, a CD4/CD8 ratio more than 1, the lack of 17p and 11q deletions and of complex karyotypic aberrations, and the occurrence of the 13q14 deletion. No case displayed the VH3-21 gene, linked in mutated CLL with a poor outcome. In addition, the VH1-69 gene associated with unmutated CLL cases was never detected. These biologic features were coupled with an indolent clinical course characterized by an unmodified clinical stage over time, and by lack of autoimmune phenomena and of major infections requiring parental antibiotics. At a time when aggressive therapeutic strategies are always more frequently used in the management of CLL, the distinctive features of patients with long-lived stable disease should be prospectively identified at presentation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12676780     DOI: 10.1182/blood-2002-12-3639

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.

Authors:  Ilaria Del Giudice; Francesca Romana Mauro; Maria Stefania De Propris; Simona Santangelo; Marilisa Marinelli; Nadia Peragine; Valeria Di Maio; Mauro Nanni; Rita Barzotti; Francesca Mancini; Daniele Armiento; Francesca Paoloni; Anna Guarini; Robin Foà
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

Review 2.  Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

3.  A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL).

Authors:  Stefano Molica; Diana Giannarelli; Luciano Levato; Rosanna Mirabelli; Massimo Gentile; Mirella Lentini; Fortunato Morabito
Journal:  Int J Hematol       Date:  2014-07-27       Impact factor: 2.490

4.  Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior.

Authors:  Mi-Ae Jang; Eun-Hyung Yoo; Kihyun Kim; Won Seog Kim; Chul Won Jung; Sun-Hee Kim; Hee-Jin Kim
Journal:  Int J Hematol       Date:  2013-02-12       Impact factor: 2.490

5.  Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Authors:  Jennifer A Woyach; Kelly Smucker; Lisa L Smith; Arletta Lozanski; Yiming Zhong; Amy S Ruppert; David Lucas; Katie Williams; Weiqiang Zhao; Laura Rassenti; Emanuela Ghia; Thomas J Kipps; Rose Mantel; Jeffrey Jones; Joseph Flynn; Kami Maddocks; Susan O'Brien; Richard R Furman; Danelle F James; Fong Clow; Gerard Lozanski; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2014-01-10       Impact factor: 22.113

6.  High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.

Authors:  Bing Cui; Emanuela M Ghia; Liguang Chen; Laura Z Rassenti; Christopher DeBoever; George F Widhopf; Jian Yu; Donna S Neuberg; William G Wierda; Kanti R Rai; Neil E Kay; Jennifer R Brown; Jeffrey A Jones; John G Gribben; Kelly A Frazer; Thomas J Kipps
Journal:  Blood       Date:  2016-11-04       Impact factor: 22.113

7.  Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.

Authors:  Monica Messina; Ilaria Del Giudice; Hossein Khiabanian; Davide Rossi; Sabina Chiaretti; Silvia Rasi; Valeria Spina; Antony B Holmes; Marilisa Marinelli; Giulia Fabbri; Alfonso Piciocchi; Francesca R Mauro; Anna Guarini; Gianluca Gaidano; Riccardo Dalla-Favera; Laura Pasqualucci; Raul Rabadan; Robin Foà
Journal:  Blood       Date:  2014-02-18       Impact factor: 22.113

Review 8.  Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia.

Authors:  Clive S Zent; Neil E Kay
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 9.  Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.

Authors:  Chuang Sun; Gianpietro Dotti; Barbara Savoldo
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

10.  Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma.

Authors:  Avery Sonnenberg; Jennifer Y Marciniak; Elaine A Skowronski; Sareh Manouchehri; Laura Rassenti; Emanuela M Ghia; George F Widhopf; Thomas J Kipps; Michael J Heller
Journal:  Electrophoresis       Date:  2014-05-14       Impact factor: 3.535

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.